Icatibant
In the US, Icatibant (icatibant systemic) is a member of the drug class miscellaneous cardiovascular agents and is used to treat Hereditary Angioedema.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
B06AC02
CAS registry number (Chemical Abstracts Service)
0130308-48-4
Chemical Formula
C59-H89-N19-O13-S
Molecular Weight
1305
Therapeutic Categories
Treatment of hereditary angioedema
Bradykinin receptor B2 antagonist
Chemical Names
(R)-arginyl-(S)-arginyl-(S)-prolyl-(2S,4R)-(4-hydroxyprolyl)glycyl-(S)-[3-(2-tienyl)alanyl]-(S)-seryl-(R)-[(1,2,3,4-tetrahydro-3-isochinolyl)carbonyl]-(2S,3aS,7aS)-[(hexahydro-2-indolin-3-yl)carbonyl]-(S)-arginin (IUPAC)
(R)-Arginyl-(S)-arginyl-(S)-prolyl-(2S,4R)-(4-hydroxyprolyl)glycyl-(S)-[3-(2-tienyl)alanyl]-(S)-seryl-(R)-[(1,2,3,4-tetrahydro-3-isoquinolyl)carbonyl]-(2S,3aS,7aS)-[(hexahydro-2-indolinyl)carbonyl]-(S)-arginine (WHO)
D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-tienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-L-arginine
L-arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-tienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl- (CAS)
Foreign Names
- Icatibantum (Latin)
- Icatibant (German)
- Icatibant (French)
- Icatibanto (Spanish)
Generic Names
- Icatibant (OS: BAN)
- HOE 140 (IS)
- Hoec (IS)
- Hoechst 140 (IS)
- JE-049 (Jerini) (IS)
- Icatibant Acetate (OS: USAN, BANM)
Brand Names
- Firazyr
Shire, Brazil; Shire, Finland; Shire, Norway; Shire, New Zealand; Shire, Poland; Shire, Romania; Shire Denmark, Denmark; Shire Human Genetic Therapies, Serbia; Shire Orphan Therapien GmbH, Greece; Shire Orphan Therapies GmbH, Croatia (Hrvatska); Shire, Australia; Shire, Czech Republic; Shire, Estonia; Shire, Spain; Shire, France; Shire, Lithuania; Shire, United States; Shire Argentina, Argentina; Shire Colombia, Colombia; Shire Deutschland, Germany; Shire Human Genetic Therapies, United Kingdom; Shire Human Genetic Therapies, Sweden; Shire Orphan, Slovenia; Shire Orphan Therapies, Belgium; Shire Pharma, Canada; Shire Pharmaceuticals Ireland, Ireland - Firazyr 30 mg
Shire Pharmaceutical Contracts Ltd., Hungary - Firazyr 30mg
Shire, Israel; Shire Orphan, Austria - Firazyr 30mg/3ml
Shire, Switzerland; Shire, Luxembourg
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| CAS | Chemical Abstracts Service |
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
